TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8831436

Group type: EXPERIMENTAL
Intervention: Combination of interpersonal psychotherapy and tricyclic antidepressant (nortriptyline for elderly, imipramine for midlife) during acute-phase therapy
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Continuation treatment with the same therapy
Number of subjects: 362
Study: 1434328

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 265
Study: 3883918

Group type: EXPERIMENTAL
Intervention: Seatone (green-lipped mussel extract)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31314966

Group type: EXPERIMENTAL
Intervention: Baseline testing plus annual testing, eligibility for universal ART, and patient-centered care (intervention group)
Number of subjects: 150395

Group type: COMPARATOR
Intervention: Baseline HIV and multidisease testing and national guideline-restricted ART (control group)
Number of subjects: 150395
Study: 29777115

Group type: EXPERIMENTAL
Intervention: Exergaming training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 9
Study: 27118441

Group type: EXPERIMENTAL
Intervention: Cetuximab + PX-866 (arm A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cetuximab alone (arm B)
Number of subjects: 85
Study: 24559035

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counselor Satisfaction Ratings
Number of subjects: 0
Study: 22651541

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol 250/50 mcg (FSC)
Number of subjects: 214524

Group type: COMPARATOR
Intervention: Anticholinergics (ACs)
Number of subjects: 214524
Study: 19487628

Group type: EXPERIMENTAL
Intervention: Post-FDA advisory trends
Number of subjects: 792
Study: 17194834

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 300
Study: 14693626

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 2.5 mg (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 2.5 mg (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal levobupivacaine 2.5 mg (group L)
Number of subjects: 60
Study: 11668132

Group type: EXPERIMENTAL
Intervention: Thyroxine 100 microgram
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9520073

Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR) after standard breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR) in fasted condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide formulation (Madopar DR) with food
Number of subjects: 12
Study: 7737238

Group type: EXPERIMENTAL
Intervention: 50 mg tiracizine hydrochloride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg tiracizine hydrochloride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 mg tiracizine hydrochloride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tiracizine (all doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tiracizine (serum concentrations about 80 ng/ml)
Number of subjects: 8
Study: 2537562

Group type: EXPERIMENTAL
Intervention: Enalapril plus diuretics (n = 72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Digoxin plus diuretics (n = 70)
Number of subjects: 142
Study: 31748939

Group type: EXPERIMENTAL
Intervention: Pre-release methadone treatment
Number of subjects: 114
Study: 30079791

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 154

Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 154
Study: 27511904

Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both DA and UC
Number of subjects: 200
Study: 26179184

Group type: EXPERIMENTAL
Intervention: Inotropic therapy (Milrinone in 84.8% and Dobutamine in 15.2%)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Inotropic therapy as a bridge to transplant/LVAD
Number of subjects: 197
Study: 24119693

Group type: EXPERIMENTAL
Intervention: Lactate clearance rate (LCR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Central venous oxygen saturation (ScvO2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: LCR
Number of subjects: 50

Group type: COMPARATOR
Intervention: LCR and ScvO2
Number of subjects: 50
Study: 20833488

Group type: EXPERIMENTAL
Intervention: Dietary soy supplementation (90 mg of isoflavone)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (1mg estradiol and 0.5mg norethisterone acetate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18408610

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH; Ritalin; 20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA; 20 mg)
Number of subjects: 8
Study: 15651723

Group type: EXPERIMENTAL
Intervention: Once-daily regimen of 2 mg trichlormethiazide
Number of subjects: 85

Group type: COMPARATOR
Intervention: Twice-daily regimen of 2 mg trichlormethiazide
Number of subjects: 85
Study: 12923219

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CLA isomer trans-10, cis-12
Number of subjects: 13

Group type: COMPARATOR
Intervention: CLA supplementation
Number of subjects: 13
Study: 10891662

Group type: EXPERIMENTAL
Intervention: Suppressive doses of levothyroxine for 18 months
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Suppressive doses of levothyroxine
Number of subjects: 123
Study: 8654630

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (surgery)
Number of subjects: 20
Study: 1846783

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET) infusion at low dose (0.5 ng/min/100 ml forearm tissue)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET) infusion at high doses (25 and 50 ng/min/100 ml forearm tissue)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nifedipine (6 micrograms/min/100 ml forearm tissue)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Verapamil (80 micrograms/min/100 ml forearm tissue)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.6 micrograms/min/100 ml forearm tissue)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acetylcholine (16 micrograms/min/100 ml forearm tissue)
Number of subjects: 25
Study: 6357805

Group type: COMPARATOR
Intervention: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse.
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin.
Number of subjects: 119

Group type: COMPARATOR
Intervention: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses, followed by CMF regimen until relapse (group A).
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Vincristine 1.4 mg/m2 i.v. on days 1 and 8 during treatment with adriamycin (group AV).
Number of subjects: 119

Group type: COMPARATOR
Intervention: Adriamycin 70 mg/m2 i.v. on day 1 of a 3-week cycle for 8 courses (group A).
Number of subjects: 119
Study: 30606237

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) granules (4.9 g twice daily) plus salmeterol/fluticasone propionate combination for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matched placebo plus salmeterol/fluticasone propionate combination for 12 weeks
Number of subjects: 60
Study: 26300464

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with ingenol mebutate gel (0.015% and 0.05%)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Sequential treatment with ingenol mebutate gel (0.015% and 0.05%)
Number of subjects: 199
Study: 23903802

Group type: EXPERIMENTAL
Intervention: Oral paricalcitol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral calcitriol
Number of subjects: 26
Study: 22932160

Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (AT+RT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 58
Study: 19574868

Group type: EXPERIMENTAL
Intervention: Ultrasound machine models with the simplest ergonomic design and user interface
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Largest, most complex ultrasound machine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All machine models
Number of subjects: 26
Study: 16466169

Group type: EXPERIMENTAL
Intervention: Feiji Recipe (FJR) and chemotherapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 102
Study: 12504039

Group type: EXPERIMENTAL
Intervention: Conventional fractionation radiation therapy (Arm A)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Split‐course accelerated hyperfractionated RT (Arm B)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Conventional fractionation RT plus concomitant chemotherapy (Arm C)
Number of subjects: 192
Study: 10817001

Group type: EXPERIMENTAL
Intervention: Alfentanyl (bolus dose of 50 micrograms.kg‐1 and continuous infusion of 0.50 microgram.kg‐1.min‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl (bolus dose of 5 micrograms.kg‐1 and continuous infusion of 0.16 microgram.kg‐1.min‐1)
Number of subjects: 100
Study: 8776186

Group type: EXPERIMENTAL
Intervention: Heparin-coated group (Group H)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 1498061

Group type: EXPERIMENTAL
Intervention: 9 intravenous CMF courses (cyclophosphamide, methotrexate, 5FU) - 113 patients
Number of subjects: 228

Group type: COMPARATOR
Intervention: 3 courses of MTV (mitomycin C, thiotepa, vindesine) plus 3 courses of EVM (epirubicin, vincristine, methotrexate) - 115 patients
Number of subjects: 228
Study: 6494455

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Megluminamidotrizoate
Number of subjects: 20
Study: 30865632

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) with sulfadoxine‐pyrimethamine plus amodiaquine given once a month for 5 months
Number of subjects: 4546

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC)
Number of subjects: 4546

Group type: COMPARATOR
Intervention: Control villages (CCM alone)
Number of subjects: 4546

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4546
Study: 27779768

Group type: EXPERIMENTAL
Intervention: Family-based education programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 27555618

Group type: EXPERIMENTAL
Intervention: Retrograde rhinopharyngeal clearance with physiological solution (0.9%) instillation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nasopharyngeal aspiration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Retrograde rhinopharyngeal clearance
Number of subjects: 100
Study: 24651230

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 12
Study: 22099529

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention at follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline assessments (prognosis and depression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life at follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression at follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social relationships needs
Number of subjects: 0
Study: 19103995

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 891

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 891
Study: 18422199

Group type: EXPERIMENTAL
Intervention: JWYY granules
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 76
Study: 15766343

Group type: EXPERIMENTAL
Intervention: KCI TheraPulse
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hill-Rom Duo mattress
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 62
Study: 14570295

Group type: EXPERIMENTAL
Intervention: Most expensive cancer screening test
Number of subjects: 781

Group type: COMPARATOR
Intervention: Less expensive cancer screening test
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Most expensive test justification
Number of subjects: 781

Group type: COMPARATOR
Intervention: Less expensive test justification
Number of subjects: 781
Study: 10827379

Group type: EXPERIMENTAL
Intervention: colestipol‐niacin
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: QCA measures of lesion progression
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: QCA measures of progression of coronary artery disease
Number of subjects: 156
Study: 8912037

Group type: EXPERIMENTAL
Intervention: Bulimic women with a past history of anorexia nervosa
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bulimic women without a past history of anorexia nervosa
Number of subjects: 114
Study: 1354088

Group type: EXPERIMENTAL
Intervention: Modified basketball shoe
Number of subjects: 390

Group type: COMPARATOR
Intervention: Standard infantry boots
Number of subjects: 390
Study: 6502317

Group type: EXPERIMENTAL
Intervention: Fenfluramine 1.5 mg/kg daily (0.75 mg/kg twice daily) for 8 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 14
Study: 31175425

Group type: EXPERIMENTAL
Intervention: Social counseling and therapy led by a social worker, six sessions of 60 min each in 3 weeks
Number of subjects: 354

Group type: COMPARATOR
Intervention: Usual care: individual counseling meeting by request
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Social counseling and therapy led by a social worker
Number of subjects: 354
Study: 30540808

Group type: EXPERIMENTAL
Intervention: ChAd63 MVA ME-TRAP
Number of subjects: 700
Study: 25996804

Group type: EXPERIMENTAL
Intervention: Elastin hydrolysate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pro‐Gly
Number of subjects: 0
Study: 24085341

Group type: COMPARATOR
Intervention: Beetroot juice containing 4.2 mmol NO(3‐) (SINGLE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Beetroot juice containing 8.4 mmol NO(3‐) (DOUBLE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0 mmol NO(3‐))
Number of subjects: 10
Study: 23066769

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 2000 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20509857

Group type: EXPERIMENTAL
Intervention: PIO (pioglitazone) 15 mg, twice a day
Number of subjects: 23

Group type: COMPARATOR
Intervention: GLIM (glimepiride) 1 mg, twice a day
Number of subjects: 23
Study: 18633055

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (basal 8 mL/h, bolus 4 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.4% ropivacaine (basal 4 mL/h, bolus 2 mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.4% ropivacaine
Number of subjects: 50
Study: 15758880

Group type: EXPERIMENTAL
Intervention: Minimally-diluted BCP supplemented with potassium-chloride and magnesium-sulfate (Group M)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard 4:1-diluted blood-crystalloid BCP (Group C)
Number of subjects: 70
Study: 11884967

Group type: EXPERIMENTAL
Intervention: biv‐WC (killed oral cholera vaccine)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: rBS‐WC (commercially available monovalent oral cholera vaccine)
Number of subjects: 247
Study: 9928759

Group type: EXPERIMENTAL
Intervention: Mesocaval interposition shunt (MIS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Repeated sclerotherapy (ST)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study: 7555507

Group type: EXPERIMENTAL
Intervention: Vitamin E (1,600 IU/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1695491

Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine at 10 micrograms
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine at 100 micrograms
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine at 1,000 micrograms
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine (all doses)
Number of subjects: 13
Study: 6968608

Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 100
Study: 29336859

Group type: EXPERIMENTAL
Intervention: Chemotherapy counselling by pharmacists based on the 'Managing Patients on Chemotherapy' module
Number of subjects: 2120

Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 2120
Study: 28510680

Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide, 150 mg twice daily for 16 weeks
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo, 150 mg twice daily for 16 weeks
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 26152766

Group type: EXPERIMENTAL
Intervention: Glucagon at euglycemia
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucagon at hypoglycemia
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hypoglycemia group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucagon doses studied in both groups
Number of subjects: 29
Study: 21923567

Group type: EXPERIMENTAL
Intervention: Topical fusidic acid cream
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Single-dose clarithromycin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 151
Study: 20935558

Group type: EXPERIMENTAL
Intervention: Vacc-4x therapeutic immunization
Number of subjects: 27
Study: 19102912

Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome (ACS)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Stable coronary artery disease (SCAD)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: High density lipoprotein‐cholesterol (HDL) levels > 1.04 mmol/L in ACS patients
Number of subjects: 210
Study: 15980998

Group type: EXPERIMENTAL
Intervention: Cervical carbon fiber cage (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Allograft with plating (n=20)
Number of subjects: 40
Study: 14568899

Group type: EXPERIMENTAL
Intervention: Velocity‐encoded CMR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Velocity‐encoded CMR (repeated for 5 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Doppler ultrasound
Number of subjects: 24
Study: 10824623

Group type: EXPERIMENTAL
Intervention: St John's Wort extract (300 mg tablet standardized to 0.3% hypericin, taken three times a day for 14 days)
Number of subjects: 13
Study: 8792755

Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study: 1352083

Group type: EXPERIMENTAL
Intervention: roxatidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 6148842

Group type: EXPERIMENTAL
Intervention: Therapist-directed prolonged exposure in vivo (PE)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Supportive therapy of dynamic type (ST)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (R)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Basal therapy (B)
Number of subjects: 103
Study: 31466618

Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy (NT-proBNP reduction to ≤1,000 pg/ml)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Usual care (GDMT alone)
Number of subjects: 638
Study: 29783077

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 162
Study: 27478305

Group type: EXPERIMENTAL
Intervention: Tr14 tablets
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 24481085

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo varnish (PV)
Number of subjects: 200
Study: 22510305

Group type: EXPERIMENTAL
Intervention: Exenatide QW (once weekly)
Number of subjects: 686
Study: 20119581

Group type: EXPERIMENTAL
Intervention: Triple H. pylori eradication therapy for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study: 18705999

Group type: EXPERIMENTAL
Intervention: Ordinal method of Whitehead
Number of subjects: 54173

Group type: EXPERIMENTAL
Intervention: Comparison of means
Number of subjects: 54173

Group type: EXPERIMENTAL
Intervention: Comparison of medians method of Payne
Number of subjects: 54173

Group type: EXPERIMENTAL
Intervention: Ordinal method for trials assessing thrombolysis
Number of subjects: 54173

Group type: COMPARATOR
Intervention: Binary method of analysis
Number of subjects: 54173
Study: 17072073

Group type: EXPERIMENTAL
Intervention: CMS patients
Number of subjects: 13
Study: 14655915

Group type: EXPERIMENTAL
Intervention: Metyrapone (4.5 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metyrapone (6.0 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11374615

Group type: EXPERIMENTAL
Intervention: Bispectral Index monitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of using Bispectral Index monitor
Number of subjects: 0